The amyloid hypothesis— beta-amyloid is the cause of AD has been the conventional wisdom. Thus, developing drugs to target beta-amyloid has been the holy grail for more than a quarter of a century.

Neither experimental early-onset mutations nor late-onset clinical trials support Cassava Sciences’ hypothesis - amyloid-beta being a causal factor for Alzheimer’s.

Researchers discover how amyloid-β and tau pathologies interact to drive early neurophysiological changes and cognitive decline in older adults at risk of Alzheimer’s disease.

Growing research shows common herpes viruses may raise dementia risk, challenging previous skepticism and opening new paths ...

“ [Autoimmune disease] includes [amyloid beta] as an important molecular player, but rejects the “amyloid hypothesis,” recognizing [amyloid beta] as a physiologically oligomerizing cytokine ...

The purity of Human Tau-441 (241-380), His Tag (Cat. No. TAU-H51H4) is greater than 95% verified by SDS-PAGE and more than 90% verified by SEC-MALS. Image Credit: ACROBiosystems ...

To test their hypothesis, the team analyzed the brain scans and cerebrospinal fluid from 598 participants in the Alzheimer’s Disease Neuroimaging Initiative study, who had amyloid plaques in ...

Even so, Bateman and many other scientists think it's too soon to abandon the amyloid hypothesis. "Penicillin, a great breakthrough, failed its first two clinical trials," Bateman says.

Roche also has several other non-Tau prospects in AD, including MorphoSys-partnered gantenerumab, an anti-beta-amyloid antibody which finished up enrolment in a phase 3 in July, but has in the ...